We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

30 hedge funds and large institutions have $135M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
30
Holders Change
+30
Holders Change %
–
% of All Funds
0.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$41.5M
2
PA
Perceptive Advisors
New York
+$35.9M
3
FI
Fosun International
China
+$13.7M
4
PC
Paulson & Co
New York
+$13.1M
5
Wells Fargo
Wells Fargo
California
+$4.21M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PHK
26
Point72 Hong Kong
Hong Kong
$89K +$83.7K +3,974 New
UBS Group
27
UBS Group
Switzerland
$56K +$52.6K +2,500 New
TRCT
28
Tower Research Capital (TRC)
New York
$7K +$6.32K +300 New
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$6K +$5.26K +250 New
CCA
30
Catalyst Capital Advisors
New York
$6K +$5.37K +255 New
1
2

DOVA Hedge Fund Activity: Q2 2017 in Review

30 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q2 2017, worth a combined $135M.

Buyers outnumbered sellers: 30 funds opened new DOVA positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $41.5M.

  • 30 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q2 2017, up from 0 in Q1 2017.
  • Funds reported $135M of Dova Pharmaceuticals, Inc. Common Stock stock for Q2 2017.
  • 30 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q2 2017 and 0 closed out, a net change of +30 holders.
  • The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $41.5M added.

Based on aggregated 13F filings for Q2 2017.